Learning Leadership with Jonathan D. Licht, MD

Oncology Overdrive

In this episode, host Shikha Jain, MD, speaks with Jonathan D. Licht, MD, about becoming and training qualified leaders in the field, challenges facing health care leaders and more. • Welcome to another exciting episode of Oncology Overdrive :58 • About Licht 1:16 • The interview 3:17 • Can you tell us about your journey into hematology-oncology and how you ended up where you are today? 3:58 • How have you found the time and ability to balance and succeed in the research, clinical, translational and leadership parts of your work? 9:05 • What do you suggest to people who are currently trying to get into leadership positions in their early-to-mid career? 12:52 • Do you agree with the sentiment that there are some leaders in the field who are put into positions prematurely or are ineffective? As a leader, how do you address the need for further training of future leaders? 18:39 • What are some of the leadership challenges you have seen in the last several years, and how have you managed to navigate them? 23:20 • How did you use your leadership skills to navigate the first few years of the pandemic, and how are you continuing to navigate delivery of care post-pandemic? 29:23 • Tell me about the process of achieving NCI designation and what it means for your institution. 36:25 • How have you had to navigate state health care legislation and policies challenging reproductive health care? 42:16 • If someone could only listen to the last minute of this episode, what would you want them to take away? 46:13 • How to contact Licht 46:56 • Thanks for listening 48:16 Jonathan D. Licht, MD, is the director of the University of Florida Health Cancer Center.

We’d love to hear from you! Send your comments/questions to Dr. Jain at [e-mail]. Follow Healio on X, formerly known as Twitter, and LinkedIn: @HemOncToday and https://www.linkedin.com/company/hemonctoday/. Follow Dr. Jain on X, formerly known as Twitter: @ShikhaJainMD. Licht can be reached on X, formerly known as Twitter, @jdlicht or via email [e-mail]. Disclosures: Jain reports no relevant financial disclosures. Licht reports consultancy for AstraZeneca and research funding for Epizyme.